[SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
D001943:Breast Neoplasms / Q000453:epidemiology; D002986:Clinical Trials as Topic; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010919:Placebos; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use*; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control*; D013997:Time Factors
D004965:Estrogen Antagonists; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride